keyword
MENU ▼
Read by QxMD icon Read
search

Empagliflozin

keyword
https://www.readbyqxmd.com/read/29679303/do-the-sglt-2-inhibitors-offer-more-than-hypoglycemic-activity
#1
REVIEW
Eduardo Flores, Carlos G Santos-Gallego, Nely Diaz-Mejía, Juan Jose Badimon
Type 2 diabetes mellitus (T2DM) is one of the most common chronic health conditions in the USA; it affects approximately 10% of adults with up to one-quarter being undiagnosed. T2DM is associated with substantial cardiovascular (CV) morbidity and mortality. T2DM is a pathological condition characterized by elevated levels of glucose and associated with high CV risk. Traditional hypoglycemic drugs have demonstrated their capability for effective and maintained management of high glucose levels, but they have not significantly impacted on the incidence of CV events...
April 20, 2018: Cardiovascular Drugs and Therapy
https://www.readbyqxmd.com/read/29667921/glycemic-control-of-type-2-diabetes-mellitus-across-stages-of-renal-impairment-information-for-primary-care-providers
#2
Lili Tong, Sharon Adler
Chronic kidney disease (CKD) is a frequent complication of type 2 diabetes mellitus (T2DM) and elevates individuals' risk for cardiovascular disease, the leading cause of morbidity and mortality in T2DM. Achieving and maintaining tight glycemic control is key to preventing development or progression of CKD; however, improving glycemic control may be limited by effects of renal impairment on the efficacy and safety of T2DM treatments, necessitating dosing adjustments and careful evaluation of contraindications...
April 18, 2018: Postgraduate Medicine
https://www.readbyqxmd.com/read/29663436/early-effects-of-empagliflozin-on-exercise-tolerance-in-patients-with-heart-failure-a-pilot-study
#3
Julio Núñez, Patricia Palau, Eloy Domínguez, Anna Mollar, Eduardo Núñez, Jose María Ramón, Gema Miñana, Enrique Santas, Lorenzo Fácila, Jose Luis Górriz, Juan Sanchis, Antoni Bayés-Genís
BACKGROUND: Sodium-glucose linked transporter 2 inhibition recently emerged as a promising therapy for reducing the risk of heart failure (HF) in patients with type 2 diabetes mellitus (T2DM). However, there is a lack of data endorsing its role in symptomatic HF patients. We sought to evaluate the short-term effects of empagliflozin on maximal exercise capacity in these patients. HYPOTHESIS: We postulate tretament with empagliflozin may improve functional capacity in patients with T2DM and established HF...
April 17, 2018: Clinical Cardiology
https://www.readbyqxmd.com/read/29627992/beneficial-effect-of-the-sglt2-inhibitor-empagliflozin-on-glucose-homeostasis-and-cardiovascular-parameters-in-the-cohen-rosenthal-diabetic-hypertensive-crdh-rat
#4
Firas Younis, Jonathan Leor, Zaid Abassi, Natalie Landa, Lea Rath, Kenneth Hollander, Nili Naftali-Shani, Talma Rosenthal
The effectiveness of empagliflozin (EMPA), a sodium glucose cotransporter type 2 inhibitor, on the kidney, pancreas, and heart was investigated in the Cohen Rosenthal diabetic hypertensive rat model (CRDH rat). Six-week-old CRDH male rats were fed a sugar diet (SD) and treated with the compound EMPA (group Drug/SD) or respective comparator with vehicle (group Veh/SD). A control group was fed a regular diet without treatment (group Veh/P). Preventive treatment with EMPA was measured during 4 months of follow-up...
January 1, 2018: Journal of Cardiovascular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/29618313/sodium-glucose-cotransporter-2-inhibitors-the-impact-on-development-and-progression-of-heart-failure
#5
Vasilios Papademetriou, Eleni Geladari
BACKGROUND: Available hypoglycemic-agents enable physicians to achieve consistent glycemic-control, but effects on cardiovascular-outcomes have been marginal or questionable. SGLT-2 inhibitors emerged as a novel antidiabetic-drug class with remarkable cardiovascular benefits, and significant improvement in the prevention and progression of HF. OBJECTIVE: The purpose of this article is to critically review the effect of SGLT-2 inhibitors on HF-outcomes and the potential underlying mechanisms...
April 4, 2018: Cardiovascular & Hematological Disorders Drug Targets
https://www.readbyqxmd.com/read/29603546/effects-of-empagliflozin-on-cardiorespiratory-fitness-and-significant-interaction-of-loop-diuretics
#6
Salvatore Carbone, Justin M Canada, Hayley E Billingsley, Dinesh Kadariya, Dave L Dixon, Cory R Trankle, Leo F Buckley, Roshanak Markley, Chau Vo, Horacio Medina de Chazal, Sanah Christopher, Raffaella Buzzetti, Benjamin W Van Tassell, Antonio Abbate
INTRODUCTION: The effects of empagliflozin on cardiorespiratory fitness in patients with type 2 diabetes mellitus (T2DM) and heart failure with reduced ejection fraction (HFrEF) are unknown. METHODS: In this pilot study we determined the effects of empagliflozin10 mg/day for four weeks on peak oxygen consumption (VO2 ) in 15 patients with T2DM and HFrEF. As exploratory analysis, we assessed whether there was an interaction for the effects of empagliflozin on peak VO2 of loop diuretics...
March 30, 2018: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/29594399/empagliflozin-metformin-and-insulin-degludec-during-pregnancy-a-case-report
#7
G Formoso, F Ginestra, G Di Dalmazi, A Consoli
No abstract text is available yet for this article.
March 29, 2018: Acta Diabetologica
https://www.readbyqxmd.com/read/29588466/canagliflozin-inhibits-interleukin-1%C3%AE-stimulated-cytokine-and-chemokine-secretion-in-vascular-endothelial-cells-by-amp-activated-protein-kinase-dependent-and-independent-mechanisms
#8
Sarah J Mancini, Daria Boyd, Omar J Katwan, Anastasiya Strembitska, Tarek A Almabrouk, Simon Kennedy, Timothy M Palmer, Ian P Salt
Recent clinical trials of the hypoglycaemic sodium-glucose co-transporter-2 (SGLT2) inhibitors, which inhibit renal glucose reabsorption, have reported beneficial cardiovascular outcomes. Whether SGLT2 inhibitors directly affect cardiovascular tissues, however, remains unclear. We have previously reported that the SGLT2 inhibitor canagliflozin activates AMP-activated protein kinase (AMPK) in immortalised cell lines and murine hepatocytes. As AMPK has anti-inflammatory actions in vascular cells, we examined whether SGLT2 inhibitors attenuated inflammatory signalling in cultured human endothelial cells...
March 27, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29580579/new-glucose-lowering-agents-for-diabetic-kidney-disease
#9
REVIEW
Lisanne C de Vos, Thushan S Hettige, Mark E Cooper
The prevalence of diabetes mellitus is increasing and is associated with a range of complications including nephropathy. New antidiabetic agents are sought which also have positive effects to diminish diabetic complications. Examples of promising new classes of such agents are glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors, and sodium-glucose cotransporter 2 inhibitors. In addition to cardiovascular protective effects such as weight loss and decreased blood pressure of some of these agents, there is evidence for renoprotective effects with these agents...
March 2018: Advances in Chronic Kidney Disease
https://www.readbyqxmd.com/read/29573118/sglt2-inhibitors-and-stroke-risk-in-patients-with-type-2-diabetes-a-systematic-review-and-meta-analysis
#10
Man Guo, Jingya Ding, Jingsong Li, Jiying Wang, Ting Zhang, Cuiping Liu, Wei Huang, Yang Long, Chenlin Gao, Yong Xu
The effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors on stroke risk have not been conclusively established. Therefore, we conducted a meta-analysis to evaluate the effects of SGLT2 inhibitors on stroke risk for patients with type 2 diabetes mellitus (T2DM) by searching available randomized trials published on the PubMed, Embase, CENTRAL, Web of Science, Scopus, and ClinicalTrials.gov databases. We identified 32 eligible trials enrolling 75,540 participants. The stroke incidence in groups receiving SGLT2 inhibitor monotherapy or combination therapy did not significantly differ from that in control groups, with relative risk (RR)=1...
March 23, 2018: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/29569378/rates-of-myocardial-infarction-and-stroke-in-patients-initiated-on-sglt2-inhibitors-versus-other-glucose-lowering-agents-in-real-world-clinical-practice-results-from-the-cvd-real-study
#11
Mikhail Kosiborod, Kåre I Birkeland, Matthew A Cavender, Alex Z Fu, John P Wilding, Kamlesh Khunti, Reinhard W Holl, Anna Norhammar, Marit Eika Jørgensen, Eric T Wittbrodt, Marcus Thuresson, Johan Bodegård, Niklas Hammar, Peter Fenici
The multinational, observational CVD-REAL study recently showed that initiation of sodium-glucose co-transporter-2 inhibitors (SGLT-2i) was associated with significantly lower rates of death and heart failure vs. other glucose-lowering drugs (oGLDs). This sub-analysis of CVD-REAL sought to determine the association between initiation of SGLT-2i vs. oGLDs and rates of myocardial infarction (MI) and stroke. Medical records, claims and national registers from the US, Sweden, Norway and Denmark were used to identify patients with T2D newly initiated on SGLT-2i (canagliflozin, dapagliflozin or empagliflozin) or oGLDs...
March 22, 2018: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/29564723/cardiovascular-mortality-of-oral-antidiabetic-drugs-approved-before-and-after-the-2008-us-fda-guidance-for-industry-a-systemic-review-and-meta-analysis
#12
REVIEW
Rashmi Goyat, Pragya Rai, Jongwha Chang, Charles D Ponte, Xi Tan
BACKGROUND: Both diabetes and antidiabetic drugs (ADDs) increase the risk for cardiovascular (CV) diseases. Due to the increasing concern about CV safety associated with ADDs, the US FDA revised regulatory guidelines in 2008 to include CV safety as an endpoint. OBJECTIVE: The objective of the current study was to conduct a systematic review with meta-analysis to compare CV mortality of oral ADDs approved before and after the FDA's 2008 guidance. METHODS: Three electronic databases (PubMed, Scopus, and the Clinical Trial Registry) were searched to retrieve studies published up to 24 February 2017...
March 21, 2018: Clinical Drug Investigation
https://www.readbyqxmd.com/read/29547706/clinical-implications-of-current-cardiovascular-outcome-trials-with-sodium-glucose-cotransporter-2-sglt2-inhibitors
#13
REVIEW
Soo Lim, Robert H Eckel, Kwang Kon Koh
The final goal in the management of patients with type 2 diabetes (T2D) is reduction in cardiovascular (CV) complications and total mortality. Various factors including hyperglycemia contribute to these complications and mortality directly and indirectly. In recent years, large-scale CV outcome trials with new antidiabetic medications, such as dipeptidyl peptidase-4 (DPP4) inhibitors, glucagon-like peptide-1 (GLP1) receptor agonists, and sodium glucose cotransporter-2 (SGLT2) inhibitors, have been completed...
March 8, 2018: Atherosclerosis
https://www.readbyqxmd.com/read/29540325/lower-cardiovascular-risk-associated-with-sglt-2i-in-400-000-patients-the-cvd-real-2-study
#14
Mikhail Kosiborod, Carolyn S P Lam, Shun Kohsaka, Dae Jung Kim, Avraham Karasik, Jonathan Shaw, Navdeep Tangri, Su-Yen Goh, Marcus Thuresson, Hungta Chen, Filip Surmont, Niklas Hammar, Peter Fenici
BACKGROUND: Randomized trials demonstrated lower risk of cardiovascular (CV) events with sodium-glucose cotransporter-2 inhibitors (SGLT-2i) in patients with type 2 diabetes (T2D) at high CV risk. Prior real-world data suggested similar SGLT-2i effects in T2D patients with broader risk profile, but focused on heart failure and death, and were limited to US and Europe. OBJECTIVES: To examine a broad range of CV outcomes in patients initiated on SGLT-2i vs. other glucose lowering drugs (oGLD) across six countries in Asia Pacific, Middle East and North America (NCT02993614)...
March 7, 2018: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/29528236/glycosyl-cross-coupling-with-diaryliodonium-salts-access-to-aryl-c-glycosides-of-biomedical-relevance
#15
Duk Yi, Feng Zhu, Maciej A Walczak
A stereospecific cross-coupling reaction of anomeric nucleophiles with diaryliodonium triflates resulting in the synthesis of aryl C-glycosides is reported. This process capitalizes on a stereoretentive reaction of configurationally stable C1 stannanes and is promoted by a palladium catalyst in the presence of a bulky phosphine ligand that suppresses the undesired β-elimination. The utility of this reaction has been demonstrated in the preparation of a series of C-glycosides derived from common saccharides resulting in exclusive transfer of anomeric configuration from the anomeric nucleophile to the product, and in the synthesis of empagliflozin, a commercial antidiabetic drug...
March 12, 2018: Organic Letters
https://www.readbyqxmd.com/read/29524188/adverse-drug-events-associated-with-low-dose-10-mg-versus-high-dose-25-mg-empagliflozin-in-patients-treated-for-type-2-diabetes-mellitus-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials
#16
Xia Dai, Zu-Chun Luo, Lu Zhai, Wen-Piao Zhao, Feng Huang
INTRODUCTION: Empagliflozin is a new, emerging oral hypoglycemic agent (OHA) which has shown significant benefits in type 2 diabetes mellitus (T2DM) patients with cardiovascular disease. In this analysis, our aim was to systematically compare the adverse drug events (ADEs) associated with a low (10 mg) versus a high (25 mg) dose of empagliflozin as (1) monotherapy, (2) as an add-on to other OHAs, and (3) as an add-on specifically to metformin, in patients who were treated for T2DM. METHODS: This was a systematic review and meta-analysis of randomized controlled trials that compared empagliflozin 10 mg versus 25 mg in patients who were treated for T2DM and which reported adverse drug reactions as their clinical endpoints...
March 9, 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29520964/type-2-diabetes-mellitus-and-heart-failure-a-position-statement-from-the-heart-failure-association-of-the-european-society-of-cardiology
#17
REVIEW
Petar M Seferović, Mark C Petrie, Gerasimos S Filippatos, Stefan D Anker, Giuseppe Rosano, Johann Bauersachs, Walter J Paulus, Michel Komajda, Francesco Cosentino, Rudolf A de Boer, Dimitrios Farmakis, Wolfram Doehner, Ekaterini Lambrinou, Yuri Lopatin, Massimo F Piepoli, Michael J Theodorakis, Henrik Wiggers, John Lekakis, Alexandre Mebazaa, Mamas A Mamas, Carsten Tschöpe, Arno W Hoes, Jelena P Seferović, Jennifer Logue, Theresa McDonagh, Jillian P Riley, Ivan Milinković, Marija Polovina, Dirk J van Veldhuisen, Mitja Lainscak, Aldo P Maggioni, Frank Ruschitzka, John J V McMurray
The coexistence of type 2 diabetes mellitus (T2DM) and heart failure (HF), either with reduced (HFrEF) or preserved ejection fraction (HFpEF), is frequent (30-40% of patients) and associated with a higher risk of HF hospitalization, all-cause and cardiovascular (CV) mortality. The most important causes of HF in T2DM are coronary artery disease, arterial hypertension and a direct detrimental effect of T2DM on the myocardium. T2DM is often unrecognized in HF patients, and vice versa, which emphasizes the importance of an active search for both disorders in the clinical practice...
March 8, 2018: European Journal of Heart Failure
https://www.readbyqxmd.com/read/29516230/the-heart-failure-burden-of-type-2-diabetes-mellitus-a-review-of-pathophysiology-and-interventions
#18
REVIEW
Anne Pernille Ofstad, Dan Atar, Lars Gullestad, Gisle Langslet, Odd Erik Johansen
Diabetes and heart failure (HF) are both global epidemics with tremendous costs on society with increased rates of HF hospitalizations and worsened prognosis when co-existing, making it a significant "deadly duo." The evidence for pharmacological treatment of HF in patients with type 2 diabetes mellitus (T2DM) stems typically from either subgroup analyses of patients that were recruited to randomized controlled trials of HF interventions, usually in patients with reduced ejection fraction (EF), or from subgroup analyses of HF patients recruited to cardiovascular (CV) outcome trials (CVOT) of glucose lowering agents involving patients with T2DM...
March 8, 2018: Heart Failure Reviews
https://www.readbyqxmd.com/read/29508697/corrigendum-canagliflozin-dapagliflozin-and-empagliflozin-monotherapy-for-treating-type-2-diabetes-systematic-review-and-economic-evaluation
#19
Rhona Johnston, Olalekan Uthman, Ewen Cummins, Christine Clar, Pamela Royle, Jill Colquitt, Bee Kang Tan, Andrew Clegg, Saran Shantikumar, Rachel Court, J Paul O'Hare, David McGrane, Tim Holt, Norman Waugh
No abstract text is available yet for this article.
February 2018: Health Technology Assessment: HTA
https://www.readbyqxmd.com/read/29506779/risks-of-diabetic-foot-syndrome-and-amputation-associated-with-sodium-glucose-co-transporter-2-inhibitors-a-meta-analysis-of-randomized-controlled-trials
#20
D Li, J Yufeng Yang, T Wang, S Shen, H Tang
BACKGROUND: The U.S. Food and Drug Administration recently issued a safety communication requiring new warnings of increased leg and foot amputation risk be added to canagliflozin drug labelling. However, the risk associated with other sodium-glucose co-transporter 2 inhibitors (SGLT2i) remains uncertain. AIM: This meta-analysis aimed to evaluate the potential risks of diabetic foot syndrome (DFS) and amputation associated with SGLT2i. METHODS: Relevant databases were searched from inception to June 14, 2017 to identify randomized controlled trials (RCTs) that evaluated risks of DFS and amputation associated with SGLT2i use...
February 13, 2018: Diabetes & Metabolism
keyword
keyword
44979
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"